XG005 for Pain Control in Subjects Undergoing Bunionectomy

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

450 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-08-29

Study Completion Date

2024-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate the safety, efficacy, and PK of low dose (750 mg) and high-dose (1250 mg) XG005 oral tablets compared with placebo in subjects undergoing bunionectomy. Subjects will be confined in the clinic from check-in through 72 hours post-surgery to monitor subject safety.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of XP20B Following Bunionectomy Surgery

NCT00655291

Acute Pain

COMPLETED PHASE3

Safety and Efficacy Study of COV155 for Post-operative Bunionectomy Pain

NCT01743625

Pain, Postoperative Bunion

COMPLETED PHASE3

Efficacy and Safety Study of 4975 to Manage Pain of Bunionectomy

NCT00656578

Pain

COMPLETED PHASE3

Safety and Efficacy of COV795 in Moderate to Severe Post-Operative Bunionectomy Pain With an Open-label Extension

NCT01484652

Pain, Postoperative Bunion

COMPLETED PHASE3

Multicenter Study to Evaluate the Analgesic Efficacy of XP21L in Subjects With Pain Following Bunionectomy Surgery

NCT00366444

Pain, Postoperative

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multi-center, randomized, double-blind, parallel-group, placebo-controlled study. Eligible subjects will be randomized in a 1:1:1 ratio to receive either 750 mg XG005, 1250 mg XG005, or placebo, twice a day, post bunionectomy surgery in domiciled clinic. Subjects and all study staff performing study assessments will be blinded to treatment allocation. Subjects will be discharged at a reasonable hour of the day after the end of the 72-hour treatment period.There will be a Follow-up Visit on Day 15.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

high dose

XG005 1250 mg Q12 hours

Group Type EXPERIMENTAL

XG005 tablet

Intervention Type DRUG

Subjects will receive XG005 prior to surgery and every 12 hours for 72 hours.

low dose

XG005 750 mg Q12 hours

Group Type EXPERIMENTAL

XG005 tablet

Intervention Type DRUG

Subjects will receive XG005 prior to surgery and every 12 hours for 72 hours.

Placebo tablet

Intervention Type DRUG

Subjects will receive placebo prior to surgery and every 12 hours for 72 hours.

placebo

placebo Q12 hours

Group Type PLACEBO_COMPARATOR

Placebo tablet

Intervention Type DRUG

Subjects will receive placebo prior to surgery and every 12 hours for 72 hours.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

XG005 tablet

Subjects will receive XG005 prior to surgery and every 12 hours for 72 hours.

Intervention Type DRUG

Placebo tablet

Subjects will receive placebo prior to surgery and every 12 hours for 72 hours.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Scheduled to undergo unilateral first metatarsal bunionectomy
* Have negative urine drug screen
* Non-pregnant, non-lactating

Exclusion Criteria

* Medical condition or history that in the investigator's opinion could adversely impact the subject's participation or safety
* Use of disallowed medications (e.g. pain medication, CNS active drugs such as benzodiazepines, tricyclic antidepressants, Serotonin, and norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors (SSRIs), or any other serotonergic medications, parenteral or oral corticosteroids)
* Antihypertensive agent or diabetic regimen at a dose that has not been stable for at least 30 days
* Digoxin, warfarin lithium, theophylline preparations, aminoglycosides, and all antiarrhythmics
* Monoamine oxidase inhibitors (MAOIs)
* Positive HbsAg and/or anti-HBc but negative anti-HBs
* HIV infection
* History of illicit drug use
* History of opioid dependence
* History of NSAID-induced bronchospasm or presence of nasal polyps, history of asthma or chronic rhinitis
* Significant history of allergic reactions or known intolerance to naproxen, pregabalin or any gabapentinoid, or to any rescue medication used in the study, or any medication used in the surgical and anesthetic protocol.
* Presence of severe depression as indicated by Patient Health Questionnaire (PHQ 9) total score of ≥20 or item 9 score \>0
* Presence of severe anxiety as indicated by General Anxiety Disorder (GAD-7) score of ≥15
* Presence of history of suicidal behavior or ideation as indicated by the C-SSRS

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No